High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL
Prospective, Multicenter, Randomized ,Open-labeled, Phase III Study Comparing High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for the Prophylaxis of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma
Sponsor: Chonnam National University Hospital
A PHASE3 clinical study on DLBCL, this trial is ongoing. The trial is conducted by Chonnam National University Hospital and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chonnam National University Hospital
- Consortium for Improving Survival of Lymphoma
For direct contact, visit the study record on ClinicalTrials.gov .